Lynparza shows promise in preventing cancer recurrence
Lynparza is the first medicine targeting BRCA mutations to show clinical benefit in adjuvant setting - News - PharmaTimes
Stay updated with breaking news from Dave Fredrickson. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Lynparza is the first medicine targeting BRCA mutations to show clinical benefit in adjuvant setting - News - PharmaTimes
AstraZeneca's Tagrisso (osimertinib) has been approved in the European Union (EU) for the adjuvant treatment of adult patients with early-stage (IB, II...
Tagrisso reduced the risk of disease recurrence or death by 80% in the overall trial population of patients
EU clears Tagrisso for early-stage EGFR-mutated lung cancer 28th May 2021 The European Commission (EC) has approved AstraZeneca’s (AZ) Tagrisso for the adjuvant treatment of early-stage, epidermal growth factor receptor mutated (EGFR) non-small cell lung cancer (NSCLC) following surgery. The EC approval is based on results from the Phase III ADAURA trial, within which adjuvant treatment with Tagrisso reduced the risk of disease recurrence or death by 83% in patients with Stage II and IIIA disease, and by 80% in the overall trial population in patients with Stage IB-IIIA disease. In addition...
AZ’s Tagrisso approved for EGFR-positive NSCLC in the EU European Commission approved Tagrisso in this setting based on positive results from the ADAURA phase 3 study AstraZeneca’s (AZ) third-generation EGFR tyrosine kinase inhibitor (TKI) Tagrisso has been approved to treat early-stage EGFR mutated non-small cell lung cancer (NSCLC) in the EU. The European Commission has approved Tagrisso (osimertinib) in this setting based on positive results from the ADAURA phase 3 study. In this trial, adjuvant Tagrisso treatment was found to reduce the risk of disease recurrence or death by 80% in t...